Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have cervical cancer that has come back, kept growing during treatment, or spread to other parts of the body
- People whose cervical cancer is one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- People who do not have any other separate primary cancers at the same time
- People who have at least one tumour that can be measured on an MRI or CT scan, based on standard measurement guidelines called RECIST
- People with a general health and activity level rated at 0 or 1 on the ECOG scale (meaning fully active or able to carry out light activity)
- People who have agreed to take part, are willing to attend follow-up appointments, and have signed a consent form
Who may not be able to join:
- People whose cervical cancer is a less common type, such as small cell carcinoma, clear cell carcinoma, or sarcoma
- People who have previously been treated with a type of cancer medicine called immune checkpoint inhibitors
- People who have health conditions that make certain drugs unsafe for them, such as liver problems or kidney problems
- People who withdraw their agreement to take part in the study
- People whom the trial doctor or researcher decides are not suitable to participate, for any reason (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 15959028989
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer; Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer; Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer; Efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.